Teclison

Executive Summary

Teclison is a private oncology company headquartered in San Diego, CA, founded in 2015. The company specializes in developing innovative cancer therapies that induce tumor necrosis and enhance antitumor immunity, with a primary focus on treating patients with liver metastasis. By leveraging mechanisms to stimulate the immune system against tumors, Teclison aims to improve outcomes and survival for cancer patients who have limited treatment options. While the company has not disclosed its stage of development or total funding, its niche approach to liver metastasis positions it in a significant unmet medical need area. The lack of publicly available pipeline or financial data suggests the company is likely in early preclinical or clinical stages, seeking to advance its lead candidate toward human trials.

Upcoming Catalysts (preview)

• Q4 2026IND Filing or Clearance for Lead Candidate50% success
• Q2 2027Series A Funding Announcement60% success
• Q3 2027Strategic Partnership or Licensing Deal for Liver Metastasis Therapy40% success